NEW BRUNSWICK, N.J.,
Jan. 25, 2022 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today announced results
for fourth-quarter and full year 2021. "Our 2021 performance
reflects continued strength across all segments of our business.
Guided by Our Credo, I am honored to assume the role of CEO,
leading our global teams in continuing our work to deliver
life-changing solutions to consumers, patients, and health care
providers" said Joaquin Duato, Chief
Executive Officer. "Given our strong results, financial profile,
and innovative pipeline we are well positioned for success in 2022
and beyond."
OVERALL
FINANCIAL RESULTS
|
|
|
Q4
|
|
Full
Year
|
($ in Millions,
except EPS)
|
2021
|
2020
|
%
Change
|
|
2021
|
2020
|
%
Change
|
Reported
Sales
|
$
24,804
|
$
22,475
|
10.4%
|
|
$
93,775
|
$
82,584
|
13.6%
|
Net
Earnings
|
4,736
|
1,738
|
172.5%
|
|
20,878
|
14,714
|
41.9%
|
EPS
(diluted)
|
$
1.77
|
$
0.65
|
172.3%
|
|
$
7.81
|
$
5.51
|
41.7%
|
|
|
|
|
|
|
|
|
|
Q4
|
|
Full
Year
|
Non-GAAP*($ in
Millions, except EPS)
|
2021
|
2020
|
%
Change
|
|
2021
|
2020
|
%
Change
|
Operational
Sales1,2
|
|
|
11.6%
|
|
|
|
12.2%
|
Adjusted Operational
Sales1,3
|
|
|
12.3%
|
|
|
|
12.8%
|
Adjusted Net
Earnings1,4
|
5,678
|
4,965
|
14.4%
|
|
26,195
|
21,433
|
22.2%
|
Adjusted EPS
(diluted)1,4
|
$
2.13
|
$
1.86
|
14.5%
|
|
$
9.80
|
$
8.03
|
22.0%
|
REGIONAL SALES
RESULTS
|
|
Q4
|
|
%
Change
|
($ in
Millions)
|
2021
|
2020
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
U.S.
|
$
12,163
|
$
11,809
|
3.0%
|
3.0
|
-
|
3.1
|
International
|
12,641
|
10,666
|
18.5%
|
21.2
|
(2.7)
|
22.4
|
Worldwide
|
$
24,804
|
$
22,475
|
10.4%
|
11.6
|
(1.2)
|
12.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Full
Year
|
|
%
Change
|
($ in
Millions)
|
2021
|
2020
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
U.S.
|
$
47,156
|
$
43,133
|
9.3%
|
9.3
|
-
|
9.5
|
International
|
46,619
|
39,451
|
18.2%
|
15.3
|
2.9
|
16.6
|
Worldwide
|
$
93,775
|
$
82,584
|
13.6%
|
12.2
|
1.4
|
12.8
|
SEGMENT SALES
RESULTS
|
|
Q4
|
|
%
Change
|
($ in
Millions)
|
2021
|
2020
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
Consumer
Health
|
$
3,657
|
$
3,618
|
1.1%
|
1.8
|
(0.7)
|
2.9
|
Pharmaceutical
|
14,288
|
12,268
|
16.5%
|
17.9
|
(1.4)
|
18.6
|
Medical
Devices
|
6,859
|
6,589
|
4.1%
|
5.3
|
(1.2)
|
5.6
|
Worldwide
|
$
24,804
|
$
22,475
|
10.4%
|
11.6
|
(1.2)
|
12.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Full
Year
|
|
%
Change
|
($ in
Millions)
|
2021
|
2020
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
Consumer
Health
|
$
14,635
|
$
14,053
|
4.1%
|
2.8
|
1.3
|
3.8
|
Pharmaceutical
|
52,080
|
45,572
|
14.3%
|
13.1
|
1.2
|
13.6
|
Medical
Devices
|
27,060
|
22,959
|
17.9%
|
16.2
|
1.7
|
16.8
|
Worldwide
|
$
93,775
|
$
82,584
|
13.6%
|
12.2
|
1.4
|
12.8
|
|
1 Non-GAAP
financial measure; refer to reconciliations of non-GAAP financial
measures included in accompanying schedules
|
2 Excludes
the impact of translational currency
|
3 Excludes
the net impact of acquisitions and divestitures and translational
currency
|
4 Excludes
intangible amortization expense and special items
|
Note: values
may have been rounded
|
FULL YEAR 2021 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide adjusted
operational sales increased 3.8%* primarily driven by
over-the-counter (OTC) products including TYLENOL analgesics and
digestive health, in addition to NEUTROGENA and AVEENO products in
Skin Health / Beauty primarily due to COVID-19 market recovery. The
growth was partially offset by external supply constraints mainly
impacting Skin Health / Beauty.
Pharmaceutical
Pharmaceutical worldwide adjusted
operational sales grew 13.6%* driven by DARZALEX (daratumumab), a
biologic for the treatment of multiple myeloma, STELARA
(ustekinumab), a biologic for the treatment of a number of
immune-mediated inflammatory diseases, TREMFYA (guselkumab), a
biologic for the treatment of adults living with moderate to severe
plaque psoriasis, and for adults with active psoriatic arthritis,
ERLEADA (apalutamide), a next-generation androgen receptor
inhibitor for the treatment of patients with prostate cancer, and
INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone
palmitate), long-acting, injectable atypical antipsychotics for the
treatment of schizophrenia in adults. Also contributing to growth
were sales of the Janssen COVID-19 Vaccine (Ad26.COV2.S) for the
treatment of the SARS-CoV-2 virus. This growth was partially offset
by declines in U.S. sales of REMICADE (infliximab), a biologic
approved for the treatment of a number of immune-mediated
inflammatory diseases.
Medical Devices
Medical Devices worldwide adjusted
operational sales grew 16.8%*, driven primarily by the market
recovery from COVID-19 impacts and the associated deferral of
medical procedures in the prior year across all of our businesses
including Surgery, Interventional Solutions, Vision and
Orthopaedics.
NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:
The
information contained in this section should be read in conjunction
with Johnson & Johnson's other disclosures filed with the
Securities and Exchange Commission, including its Current Reports
on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on
Form 10-K. Copies of these filings are available online at
www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
The reader is also encouraged to review all other news releases and
information available in the Investors section of the company's
website at news releases, as well as
www.factsabouttalc.com,www.factsaboutourprescriptionopioids.com,
and www.LTLManagementInformation.com.
Regulatory
Decisions
|
European Commission
Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the
Maintenance Treatment of Schizophrenia in Adults
|
(press
release)
|
U.S. FDA Approves
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in
Combination with Carfilzomib and Dexamethasone for Patients with
Multiple Myeloma After First or Subsequent Relapse
|
(press
release)
|
Janssen EMEA Receives
Conditional Marketing Authorisation for RYBREVANT®
(amivantamab), the
First Treatment Approved for Patients with Advanced NonSmall Cell
Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations After
Failure of Platinum-Based Therapy
|
(press
release)
|
Johnson & Johnson
COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S.
FDA
|
(press
release)
|
World Health
Organization Strategic Advisory Group of Experts (SAGE) Interim
Recommendation Supports Use of Johnson & Johnson COVID-19
Vaccine as a Booster
|
(press
release)
|
Johnson & Johnson
Announces Positive CHMP Opinion for a Booster Shot of its COVID-19
Vaccine
|
(press
release)
|
FDA Approves Two New
Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat
Blood Clots in Pediatric Patients
|
(press
release)
|
U.S. FDA Approves New
MENTOR® MemoryGel BOOST™ Breast Implant1
|
(press
release)
|
Regulatory
Submissions
|
Janssen Seeks
Approval of IMBRUVICA® (ibrutinib) in a Fixed-Duration Regimen for
Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)
(EU)
|
(press
release)
|
Janssen Submits
Biologics License Application to U.S. FDA Seeking Approval of
Teclistamab for the Treatment of Patients with Relapsed or
Refractory Multiple Myeloma
|
(press
release)
|
Other
|
Johnson & Johnson
Announces Plans to Accelerate Innovation, Serve Patients and
Consumers, and Unlock Value through Intent to Separate Consumer
Health Business
|
(press
release)
|
Johnson & Johnson
Appoints Senior Leaders to Executive Committee
|
(press
release)
|
Johnson & Johnson
announces significant progress towards its climate goals – 100%
renewable electricity for all sites in the United States, Canada
and Europe by 2023
|
(press
release)
|
Johnson & Johnson
Medical Devices Companies Announces Strategic Partnership with
Microsoft to Further Enable its Digital Surgery
Solutions1
|
(press
release)
|
Johnson & Johnson
COVID-19 Booster, Administered Six Months After Two-Dose Regimen of
BNT162b2, Shows Substantial Increase in Antibody and T-cell
Responses
|
(press
release)
|
Johnson & Johnson
Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine
for the World's Most Vulnerable People through Novel Humanitarian
Buffer
|
(press
release)
|
Johnson & Johnson
COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against
Hospitalization in South Africa when Omicron was
Dominant
|
(press
release)
|
1Subsequent to the quarter
|
FULL-YEAR 2022 GUIDANCE:
Johnson & Johnson does
not provide GAAP financial measures on a forward-looking basis
because the company is unable to predict with reasonable certainty
the ultimate outcome of legal proceedings, unusual gains and
losses, acquisition-related expenses and purchase accounting fair
value adjustments without unreasonable effort. These items are
uncertain, depend on various factors, and could be material to
Johnson & Johnson's results computed in accordance with
GAAP.
($ in Billions,
except
EPS)
|
January
2022
(ex. COVID
Vx)
|
January
2022
(COVID
Vx)
|
January
2022
(incl. COVID
Vx)
|
Adjusted Operational
Sales1,2
Change vs. Prior
Year
|
6.5% –
7.5%
|
|
7.0% –
8.5%
|
Operational
Sales2
Change vs. Prior
Year
|
$97.3B –
$98.3B
6.5% –
7.5%
|
$3.0B -
$3.5B
|
$100.3B –
$101.8B
7.0% –
8.5%
|
Estimated Reported
Sales3
Change vs. Prior
Year
|
$95.9B -
$96.9B
5.0% –
6.0%
|
$3.0B -
$3.5B
|
$98.9B -
$100.4B
5.5% –
7.0%
|
|
|
|
|
Adjusted Operational
EPS (Diluted)2,4
Change vs. Prior
Year
|
|
|
$10.60 -
$10.80
8.2% –
10.2%
|
Adjusted EPS
(Diluted)3,4
Change vs. Prior
Year
|
|
|
$10.40 -
$10.60
6.1% –
8.2%
|
1 Non-GAAP
financial measure; excludes the net impact of acquisitions and
divestitures
|
2 Non-GAAP
financial measure; excludes the impact of translational
currency
|
3 Calculated using Euro Average Rate:
January 2022 = $1.14 (Illustrative purposes only)
|
4
Non-GAAP financial measure; excludes intangible amortization
expense and special items
|
Note: % may
have been rounded
|
Other modeling considerations will be provided on the
webcast.
WEBCAST INFORMATION:
Johnson & Johnson will
conduct a conference call with investors to discuss this earnings
release today at 8:30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and
other interested parties may be accessed by visiting the Johnson
& Johnson Website. A replay and podcast will be available
approximately two hours after the live webcast in the Investors
section of the company's website at
events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson,
we believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world's largest and most broadly-based
health care company, we are committed to using our reach and size
for good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity.
NON-GAAP FINANCIAL MEASURES:
* "Operational sales
growth" excluding the impact of translational currency, "adjusted
operational sales growth" excluding the net impact of acquisitions
and divestitures and translational currency, as well as "adjusted
net earnings", "adjusted diluted earnings per share" and "adjusted
operational diluted earnings per share" excluding after-tax
intangible amortization expense and special items, are non-GAAP
financial measures and should not be considered replacements for,
and should be read together with, the most comparable GAAP
financial measures. Except for guidance measures, reconciliations
of these non-GAAP financial measures to the most directly
comparable GAAP financial measures can be found in the accompanying
financial schedules of the earnings release and the Investors
section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings
release are available on the company's website at
quarterly-results. These schedules include supplementary sales
data, a condensed consolidated statement of earnings,
reconciliations of non-GAAP financial measures, and sales of key
products/franchises. Additional information on Johnson &
Johnson, including adjusted income before tax by segment, a
pharmaceutical pipeline of selected compounds in late stage
development and a copy of today's earnings call presentation can
also be found in the Investors section of the company's website at
quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS:
This press release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995 regarding, among other things: future operating and
financial performance, product development, market position,
business strategy, and the anticipated separation of the company's
Consumer Health business. The reader is cautioned not to rely on
these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions
prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the
expectations and projections of Johnson & Johnson. Risks and
uncertainties include, but are not limited to: risks related to the
impact of the COVID-19 global pandemic, such as the scope and
duration of the outbreak, government actions and restrictive
measures implemented in response, material delays and cancellations
of medical procedures, supply chain disruptions and other impacts
to the business, or on the company's ability to execute business
continuity plans, as a result of the COVID-19 pandemic; economic
factors, such as interest rate and currency exchange rate
fluctuations; competition, including technological advances, new
products and patents attained by competitors; challenges inherent
in new product research and development, including uncertainty of
clinical success and obtaining regulatory approvals; uncertainty of
commercial success for new and existing products; challenges to
patents; the impact of patent expirations; the ability of the
company to successfully execute strategic plans, including
restructuring plans; the impact of business combinations and
divestitures; manufacturing difficulties or delays, internally or
within the supply chain; product efficacy or safety concerns
resulting in product recalls or regulatory action; significant
adverse litigation or government action, including related to
product liability claims; changes to applicable laws and
regulations, including tax laws and global health care reforms;
trends toward health care cost containment; changes in behavior and
spending patterns of purchasers of health care products and
services; financial instability of international economies and
legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies; the company's ability to
satisfy the necessary conditions to consummate the separation of
the company's Consumer Health business on a timely basis or at all;
the company's ability to successfully separate the company's
Consumer Health business and realize the anticipated benefits from
the separation; and the New Consumer Health Company's ability to
succeed as a standalone publicly traded company. A further list and
descriptions of these risks, uncertainties and other factors can be
found in Johnson & Johnson's Annual Report on Form 10-K for the
fiscal year ended January 3, 2021
including in the sections captioned "Cautionary Note Regarding
Forward-Looking Statements" and "Item 1A. Risk Factors," and in the
company's subsequent Quarterly Reports on Form 10-Q and other
filings with the Securities and Exchange Commission. Copies of
these filings are available online at www.sec.gov, www.jnj.com or
on request from Johnson & Johnson. Any forward-looking
statement made in this release speaks only as of the date of this
release. Johnson & Johnson does not undertake to update any
forward-looking statement as a result of new information or future
events or developments.
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2021
|
|
2020
|
|
Total
|
|
Operations
|
|
Currency
|
|
2021
|
|
2020
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
Health
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
1,529
|
|
1,509
|
|
1.3
|
%
|
1.3
|
|
-
|
|
$
6,516
|
|
6,362
|
|
2.4
|
%
|
2.4
|
|
-
|
International
|
2,128
|
|
2,109
|
|
0.9
|
|
2.1
|
|
(1.2)
|
|
8,119
|
|
7,691
|
|
5.6
|
|
3.1
|
|
2.5
|
|
3,657
|
|
3,618
|
|
1.1
|
|
1.8
|
|
(0.7)
|
|
14,635
|
|
14,053
|
|
4.1
|
|
2.8
|
|
1.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
7,418
|
|
7,116
|
|
4.2
|
|
4.2
|
|
-
|
|
27,954
|
|
25,735
|
|
8.6
|
|
8.6
|
|
-
|
International
|
6,870
|
|
5,152
|
|
33.4
|
|
36.9
|
|
(3.5)
|
|
24,126
|
|
19,837
|
|
21.6
|
|
18.8
|
|
2.8
|
|
14,288
|
|
12,268
|
|
16.5
|
|
17.9
|
|
(1.4)
|
|
52,080
|
|
45,572
|
|
14.3
|
|
13.1
|
|
1.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
Devices
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,216
|
|
3,184
|
|
1.0
|
|
1.0
|
|
-
|
|
12,686
|
|
11,036
|
|
14.9
|
|
14.9
|
|
-
|
International
|
3,643
|
|
3,405
|
|
7.0
|
|
9.3
|
|
(2.3)
|
|
14,374
|
|
11,923
|
|
20.6
|
|
17.3
|
|
3.3
|
|
6,859
|
|
6,589
|
|
4.1
|
|
5.3
|
|
(1.2)
|
|
27,060
|
|
22,959
|
|
17.9
|
|
16.2
|
|
1.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
12,163
|
|
11,809
|
|
3.0
|
|
3.0
|
|
-
|
|
47,156
|
|
43,133
|
|
9.3
|
|
9.3
|
|
-
|
International
|
12,641
|
|
10,666
|
|
18.5
|
|
21.2
|
|
(2.7)
|
|
46,619
|
|
39,451
|
|
18.2
|
|
15.3
|
|
2.9
|
Worldwide
|
$
24,804
|
|
22,475
|
|
10.4
|
%
|
11.6
|
|
(1.2)
|
|
$
93,775
|
|
82,584
|
|
13.6
|
%
|
12.2
|
|
1.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:
Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2021
|
|
2020
|
|
Total
|
|
Operations
|
|
Currency
|
|
2021
|
|
2020
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
12,163
|
|
11,809
|
|
3.0
|
%
|
3.0
|
|
-
|
|
$
47,156
|
|
43,133
|
|
9.3
|
%
|
9.3
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
6,925
|
|
5,271
|
|
31.4
|
|
34.7
|
|
(3.3)
|
|
23,594
|
|
18,980
|
|
24.3
|
|
20.7
|
|
3.6
|
Western Hemisphere
excluding U.S.
|
1,459
|
|
1,404
|
|
3.9
|
|
5.0
|
|
(1.1)
|
|
5,750
|
|
5,335
|
|
7.8
|
|
7.3
|
|
0.5
|
Asia-Pacific,
Africa
|
4,257
|
|
3,991
|
|
6.6
|
|
9.0
|
|
(2.4)
|
|
17,275
|
|
15,136
|
|
14.1
|
|
11.4
|
|
2.7
|
International
|
12,641
|
|
10,666
|
|
18.5
|
|
21.2
|
|
(2.7)
|
|
46,619
|
|
39,451
|
|
18.2
|
|
15.3
|
|
2.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$
24,804
|
|
22,475
|
|
10.4
|
%
|
11.6
|
|
(1.2)
|
|
$
93,775
|
|
82,584
|
|
13.6
|
%
|
12.2
|
|
1.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:
Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
FOURTH
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
24,804
|
|
100.0
|
|
$
22,475
|
|
100.0
|
|
10.4
|
Cost of products
sold
|
7,955
|
|
32.1
|
|
7,814
|
|
34.8
|
|
1.8
|
Gross
Profit
|
16,849
|
|
67.9
|
|
14,661
|
|
65.2
|
|
14.9
|
Selling, marketing
and administrative expenses
|
7,154
|
|
28.9
|
|
6,457
|
|
28.7
|
|
10.8
|
Research and
development expense
|
4,720
|
|
19.0
|
|
4,032
|
|
17.9
|
|
17.1
|
In-process
research and development
|
0
|
|
0.0
|
|
37
|
|
0.2
|
|
|
Interest (income)
expense, net
|
47
|
|
0.2
|
|
74
|
|
0.3
|
|
|
Other (income)
expense, net
|
9
|
|
0.0
|
|
2,354
|
|
10.5
|
|
|
Restructuring
|
83
|
|
0.3
|
|
60
|
|
0.3
|
|
|
Earnings before
provision for taxes on income
|
4,836
|
|
19.5
|
|
1,647
|
|
7.3
|
|
193.6
|
Provision
for/(Benefit from) taxes on income
|
100
|
|
0.4
|
|
(91)
|
|
(0.4)
|
|
(209.9)
|
Net
earnings
|
$
4,736
|
|
19.1
|
|
$
1,738
|
|
7.7
|
|
172.5
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
1.77
|
|
|
|
$
0.65
|
|
|
|
172.3
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,670.2
|
|
|
|
2,669.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
2.1
|
%
|
|
|
(5.5)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
6,339
|
|
25.6
|
|
$
5,601
|
|
24.9
|
|
13.2
|
Net
earnings
|
$
5,678
|
|
22.9
|
|
$
4,965
|
|
22.1
|
|
14.4
|
Net earnings per
share (Diluted)
|
$
2.13
|
|
|
|
$
1.86
|
|
|
|
14.5
|
Effective tax
rate
|
10.4
|
%
|
|
|
11.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
TWELVE
MONTHS
|
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
93,775
|
|
100.0
|
|
$
82,584
|
|
100.0
|
|
13.6
|
Cost of products
sold
|
29,855
|
|
31.8
|
|
28,427
|
|
34.4
|
|
5.0
|
Gross
Profit
|
63,920
|
|
68.2
|
|
54,157
|
|
65.6
|
|
18.0
|
Selling, marketing
and administrative expenses
|
24,659
|
|
26.3
|
|
22,084
|
|
26.8
|
|
11.7
|
Research and
development expense
|
14,714
|
|
15.7
|
|
12,159
|
|
14.7
|
|
21.0
|
In-process
research and development
|
900
|
|
1.0
|
|
181
|
|
0.2
|
|
|
Interest (income)
expense, net
|
130
|
|
0.1
|
|
90
|
|
0.1
|
|
|
Other (income)
expense, net
|
489
|
|
0.5
|
|
2,899
|
|
3.5
|
|
|
Restructuring
|
252
|
|
0.3
|
|
247
|
|
0.3
|
|
|
Earnings before
provision for taxes on income
|
22,776
|
|
24.3
|
|
16,497
|
|
20.0
|
|
38.1
|
Provision for
taxes on income
|
1,898
|
|
2.0
|
|
1,783
|
|
2.2
|
|
6.4
|
Net
earnings
|
$
20,878
|
|
22.3
|
|
$
14,714
|
|
17.8
|
|
41.9
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
7.81
|
|
|
|
$
5.51
|
|
|
|
41.7
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,674.0
|
|
|
|
2,670.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
8.3
|
%
|
|
|
10.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
30,464
|
|
32.5
|
|
$
25,428
|
|
30.8
|
|
19.8
|
Net
earnings
|
$
26,195
|
|
27.9
|
|
$
21,433
|
|
26.0
|
|
22.2
|
Net earnings per
share (Diluted)
|
$
9.80
|
|
|
|
$
8.03
|
|
|
|
22.0
|
Effective tax
rate
|
14.0
|
%
|
|
|
15.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth
Quarter
|
|
Twelve Months
Ended
|
|
(Dollars in Millions
Except Per Share Data)
|
2021
|
|
2020
|
|
2021
|
|
2020
|
|
Net Earnings, after
tax- as reported
|
$4,736
|
|
$1,738
|
|
$20,878
|
|
$14,714
|
|
|
|
|
|
|
|
|
|
|
Pre-tax
Adjustments
|
|
|
|
|
|
|
|
|
Intangible Asset
Amortization expense
|
1,121
|
|
1,234
|
|
4,697
|
|
4,660
|
|
Litigation expense,
net
|
274
|
|
2,902
|
|
2,328
|
|
5,112
|
|
IPR&D
|
-
|
|
37
|
|
900
|
|
181
|
|
Restructuring
related
|
140
|
|
85
|
|
473
|
|
448
|
|
Acquisition,
integration and divestiture related ¹
|
26
|
|
14
|
|
(478)
|
|
(1,073)
|
|
(Gains)/losses on
securities
|
(198)
|
|
(373)
|
|
(533)
|
|
(547)
|
|
Medical Device
Regulation
|
73
|
|
55
|
|
234
|
|
144
|
|
Consumer Health
separation costs
|
67
|
|
-
|
|
67
|
|
-
|
|
Other
|
-
|
|
-
|
|
-
|
|
6
|
|
|
|
|
|
|
|
|
|
|
Tax
Adjustments
|
|
|
|
|
|
|
|
|
Tax impact on special
item adjustments 2
|
(184)
|
|
(606)
|
|
(1,281)
|
|
(1,608)
|
|
Tax legislation and
other tax related
|
(377)
|
|
(121)
|
|
(1,090)
|
|
(604)
|
|
Adjusted Net
Earnings, after tax
|
$5,678
|
|
$4,965
|
|
$26,195
|
|
$21,433
|
|
Average shares
outstanding (Diluted)
|
2,670.2
|
|
2,669.2
|
|
2,674.0
|
|
2,670.7
|
|
Adjusted net earnings
per share (Diluted)
|
$2.13
|
|
$1.86
|
|
$9.80
|
|
$8.03
|
|
Operational adjusted
net earnings per share (Diluted)
|
$2.18
|
|
|
|
$9.65
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
|
|
|
|
|
|
|
|
1
|
Acquisition,
integration and divestiture related for 2021 primarily includes the
gain on the divestiture of two Pharmaceutical brands outside of the
U.S. Acquisition, integration and divestiture related for 2020
primarily includes a Contingent Consideration reversal of $1,148M
related to the timing of certain developmental milestones
associated with the Auris Health acquisition.
|
|
|
|
|
|
|
|
|
|
2
|
The tax impact
related to special item adjustments reflects the current and
deferred income taxes associated with the above pre-tax special
items in arriving at adjusted earnings.
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
Operational Sales Growth
|
FOURTH
QUARTER 2021 ACTUAL vs. 2020 ACTUAL
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
Health
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
|
|
|
|
|
|
|
WW As
Reported
|
|
1.1%
|
|
16.5%
|
|
4.1%
|
|
10.4%
|
U.S.
|
|
1.3%
|
|
4.2%
|
|
1.0%
|
|
3.0%
|
International
|
|
0.9%
|
|
33.4%
|
|
7.0%
|
|
18.5%
|
|
|
|
|
|
|
|
|
|
WW
Currency
|
|
(0.7)
|
|
(1.4)
|
|
(1.2)
|
|
(1.2)
|
U.S.
|
|
-
|
|
-
|
|
-
|
|
-
|
International
|
|
(1.2)
|
|
(3.5)
|
|
(2.3)
|
|
(2.7)
|
|
|
|
|
|
|
|
|
|
WW
Operational
|
|
1.8%
|
|
17.9%
|
|
5.3%
|
|
11.6%
|
U.S.
|
|
1.3%
|
|
4.2%
|
|
1.0%
|
|
3.0%
|
International
|
|
2.1%
|
|
36.9%
|
|
9.3%
|
|
21.2%
|
|
|
|
|
|
|
|
|
|
General
Surgery
|
|
|
|
|
|
|
|
|
Advanced
Sterilization Products
|
|
|
|
|
|
0.3
|
|
0.1
|
U.S.
|
|
|
|
|
|
0.0
|
|
0.0
|
International
|
|
|
|
|
|
0.5
|
|
0.2
|
|
|
|
|
|
|
|
|
|
Skin Health /
Beauty
|
|
|
|
|
|
|
|
|
Dr. Ci Labo -
Sedona
|
|
0.7
|
|
|
|
|
|
0.1
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
1.2
|
|
|
|
|
|
0.3
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.4
|
|
0.7
|
|
0.1
|
|
0.4
|
U.S.
|
|
0.6
|
|
0.0
|
|
0.2
|
|
0.1
|
International
|
|
0.3
|
|
1.7
|
|
0.0
|
|
0.8
|
|
|
|
|
|
|
|
|
|
WW Adjusted
Operational
|
|
2.9%
|
|
18.6%
|
|
5.6%
|
|
12.3%
|
U.S.
|
|
1.9%
|
|
4.2%
|
|
1.2%
|
|
3.1%
|
International
|
|
3.6%
|
|
38.6%
|
|
9.8%
|
|
22.4%
|
|
|
|
|
|
|
|
|
|
Note:
Percentages are based on actual, non-rounded figures and may not
sum
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
Operational Sales Growth
|
TWELVE
MONTHS 2021 ACTUAL vs. 2020 ACTUAL
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
Health
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
|
|
|
|
|
|
|
WW As
Reported
|
|
4.1%
|
|
14.3%
|
|
17.9%
|
|
13.6%
|
U.S.
|
|
2.4%
|
|
8.6%
|
|
14.9%
|
|
9.3%
|
International
|
|
5.6%
|
|
21.6%
|
|
20.6%
|
|
18.2%
|
|
|
|
|
|
|
|
|
|
WW
Currency
|
|
1.3
|
|
1.2
|
|
1.7
|
|
1.4
|
U.S.
|
|
-
|
|
-
|
|
-
|
|
-
|
International
|
|
2.5
|
|
2.8
|
|
3.3
|
|
2.9
|
|
|
|
|
|
|
|
|
|
WW
Operational
|
|
2.8%
|
|
13.1%
|
|
16.2%
|
|
12.2%
|
U.S.
|
|
2.4%
|
|
8.6%
|
|
14.9%
|
|
9.3%
|
International
|
|
3.1%
|
|
18.8%
|
|
17.3%
|
|
15.3%
|
|
|
|
|
|
|
|
|
|
General
Surgery
|
|
|
|
|
|
|
|
|
Advanced
Sterilization Products
|
|
|
|
|
|
0.5
|
|
0.1
|
U.S.
|
|
|
|
|
|
0.0
|
|
0.0
|
International
|
|
|
|
|
|
1.0
|
|
0.3
|
|
|
|
|
|
|
|
|
|
Skin Health /
Beauty
|
|
|
|
|
|
|
|
|
Dr. Ci Labo -
Sedona
|
|
0.5
|
|
|
|
|
|
0.1
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
1.0
|
|
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.4
|
|
0.5
|
|
0.1
|
|
0.4
|
U.S.
|
|
0.6
|
|
0.0
|
|
0.4
|
|
0.2
|
International
|
|
0.3
|
|
1.4
|
|
0.0
|
|
0.8
|
|
|
|
|
|
|
|
|
|
WW Adjusted
Operational
|
|
3.8%
|
|
13.6%
|
|
16.8%
|
|
12.8%
|
U.S.
|
|
3.0%
|
|
8.6%
|
|
15.3%
|
|
9.5%
|
International
|
|
4.4%
|
|
20.2%
|
|
18.3%
|
|
16.6%
|
|
|
|
|
|
|
|
|
|
Note:
Percentages are based on actual, non-rounded figures and may not
sum
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
CONSUMER HEALTH
SEGMENT (2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
633
|
|
543
|
16.8%
|
16.8%
|
-
|
|
|
$
2,594
|
|
2,460
|
5.4%
|
5.4%
|
-
|
Intl
|
|
740
|
|
642
|
15.1%
|
14.9%
|
0.2%
|
|
|
2,634
|
|
2,364
|
11.4%
|
6.9%
|
4.5%
|
WW
|
|
1,373
|
|
1,185
|
15.9%
|
15.8%
|
0.1%
|
|
|
5,227
|
|
4,824
|
8.4%
|
6.2%
|
2.2%
|
SKIN HEALTH /
BEAUTY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
538
|
|
583
|
-7.8%
|
-7.8%
|
-
|
|
|
2,400
|
|
2,350
|
2.1%
|
2.1%
|
-
|
Intl
|
|
546
|
|
594
|
-8.2%
|
-6.4%
|
-1.8%
|
|
|
2,141
|
|
2,100
|
1.9%
|
-0.3%
|
2.2%
|
WW
|
|
1,084
|
|
1,177
|
-8.0%
|
-7.1%
|
-0.9%
|
|
|
4,541
|
|
4,450
|
2.0%
|
1.0%
|
1.0%
|
ORAL CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
159
|
|
173
|
-8.2%
|
-8.2%
|
-
|
|
|
637
|
|
683
|
-6.7%
|
-6.7%
|
-
|
Intl
|
|
246
|
|
264
|
-7.2%
|
-5.5%
|
-1.7%
|
|
|
1,008
|
|
958
|
5.1%
|
2.8%
|
2.3%
|
WW
|
|
405
|
|
437
|
-7.6%
|
-6.5%
|
-1.1%
|
|
|
1,645
|
|
1,641
|
0.2%
|
-1.2%
|
1.4%
|
BABY CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
90
|
|
97
|
-7.5%
|
-7.5%
|
-
|
|
|
378
|
|
376
|
0.5%
|
0.5%
|
-
|
Intl
|
|
309
|
|
310
|
-0.3%
|
1.3%
|
-1.6%
|
|
|
1,188
|
|
1,141
|
4.1%
|
3.7%
|
0.4%
|
WW
|
|
399
|
|
407
|
-2.0%
|
-0.8%
|
-1.2%
|
|
|
1,566
|
|
1,517
|
3.2%
|
2.9%
|
0.3%
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
4
|
|
3
|
14.1%
|
14.1%
|
-
|
|
|
13
|
|
13
|
-1.6%
|
-1.6%
|
-
|
Intl
|
|
230
|
|
234
|
-1.8%
|
1.2%
|
-3.0%
|
|
|
905
|
|
888
|
1.8%
|
2.0%
|
-0.2%
|
WW
|
|
233
|
|
237
|
-1.6%
|
1.3%
|
-2.9%
|
|
|
917
|
|
901
|
1.8%
|
1.9%
|
-0.1%
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
106
|
|
110
|
-4.2%
|
-4.2%
|
-
|
|
|
495
|
|
480
|
3.1%
|
3.1%
|
-
|
Intl
|
|
57
|
|
65
|
-9.6%
|
-10.2%
|
0.6%
|
|
|
243
|
|
240
|
1.7%
|
-2.7%
|
4.4%
|
WW
|
|
164
|
|
175
|
-6.2%
|
-6.4%
|
0.2%
|
|
|
739
|
|
720
|
2.6%
|
1.2%
|
1.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL CONSUMER
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,529
|
|
1,509
|
1.3%
|
1.3%
|
-
|
|
|
6,516
|
|
6,362
|
2.4%
|
2.4%
|
-
|
Intl
|
|
2,128
|
|
2,109
|
0.9%
|
2.1%
|
-1.2%
|
|
|
8,119
|
|
7,691
|
5.6%
|
3.1%
|
2.5%
|
WW
|
|
$
3,657
|
|
3,618
|
1.1%
|
1.8%
|
-0.7%
|
|
|
$
14,635
|
|
14,053
|
4.1%
|
2.8%
|
1.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
PHARMACEUTICAL
SEGMENT (2,3)
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
2,912
|
|
2,845
|
2.4%
|
2.4%
|
-
|
|
|
$
10,843
|
|
10,175
|
6.6%
|
6.6%
|
-
|
Intl
|
|
1,443
|
|
1,261
|
14.5%
|
17.9%
|
-3.4%
|
|
|
5,907
|
|
4,880
|
21.0%
|
17.7%
|
3.3%
|
WW
|
|
4,355
|
|
4,105
|
6.1%
|
7.1%
|
-1.0%
|
|
|
16,750
|
|
15,055
|
11.3%
|
10.2%
|
1.1%
|
REMICADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
511
|
|
656
|
-22.2%
|
-22.2%
|
-
|
|
|
2,019
|
|
2,508
|
-19.5%
|
-19.5%
|
-
|
US Exports
(4)
|
|
39
|
|
25
|
53.5%
|
53.5%
|
-
|
|
|
236
|
|
346
|
-31.9%
|
-31.9%
|
-
|
Intl
|
|
214
|
|
220
|
-2.3%
|
-2.4%
|
0.1%
|
|
|
935
|
|
893
|
4.8%
|
0.4%
|
4.4%
|
WW
|
|
764
|
|
901
|
-15.2%
|
-15.2%
|
0.0%
|
|
|
3,190
|
|
3,747
|
-14.9%
|
-15.9%
|
1.0%
|
SIMPONI / SIMPONI
ARIA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
287
|
|
315
|
-8.9%
|
-8.9%
|
-
|
|
|
1,127
|
|
1,155
|
-2.4%
|
-2.4%
|
-
|
Intl
|
|
271
|
|
261
|
3.6%
|
8.4%
|
-4.8%
|
|
|
1,148
|
|
1,088
|
5.5%
|
4.1%
|
1.4%
|
WW
|
|
559
|
|
576
|
-3.2%
|
-1.0%
|
-2.2%
|
|
|
2,276
|
|
2,243
|
1.4%
|
0.8%
|
0.6%
|
STELARA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,542
|
|
1,572
|
-1.9%
|
-1.9%
|
-
|
|
|
5,938
|
|
5,240
|
13.3%
|
13.3%
|
-
|
Intl
|
|
792
|
|
672
|
17.9%
|
21.7%
|
-3.8%
|
|
|
3,196
|
|
2,467
|
29.6%
|
25.9%
|
3.7%
|
WW
|
|
2,334
|
|
2,244
|
4.0%
|
5.1%
|
-1.1%
|
|
|
9,134
|
|
7,707
|
18.5%
|
17.3%
|
1.2%
|
TREMFYA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
528
|
|
276
|
90.9%
|
90.9%
|
-
|
|
|
1,503
|
|
926
|
62.3%
|
62.3%
|
-
|
Intl
|
|
165
|
|
105
|
56.9%
|
61.8%
|
-4.9%
|
|
|
624
|
|
421
|
48.2%
|
44.0%
|
4.2%
|
WW
|
|
693
|
|
382
|
81.5%
|
82.8%
|
-1.3%
|
|
|
2,127
|
|
1,347
|
57.9%
|
56.5%
|
1.4%
|
OTHER
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
6
|
|
-
|
*
|
*
|
-
|
|
|
21
|
|
-
|
*
|
*
|
-
|
Intl
|
|
0
|
|
2
|
*
|
*
|
*
|
|
|
3
|
|
11
|
-73.3%
|
-74.6%
|
1.3%
|
WW
|
|
6
|
|
2
|
*
|
*
|
*
|
|
|
24
|
|
11
|
*
|
*
|
*
|
INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
614
|
|
470
|
30.8%
|
30.8%
|
-
|
|
|
2,249
|
|
1,735
|
29.7%
|
29.7%
|
-
|
Intl
|
|
1,824
|
|
442
|
*
|
*
|
-3.0%
|
|
|
3,612
|
|
1,839
|
96.3%
|
93.4%
|
2.9%
|
WW
|
|
2,437
|
|
912
|
*
|
*
|
-1.5%
|
|
|
5,861
|
|
3,574
|
64.0%
|
62.5%
|
1.5%
|
COVID-19
VACCINE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
213
|
|
-
|
*
|
*
|
-
|
|
|
634
|
|
-
|
*
|
*
|
-
|
Intl
|
|
1,405
|
|
-
|
*
|
*
|
-
|
|
|
1,751
|
|
-
|
*
|
*
|
-
|
WW
|
|
1,619
|
|
-
|
*
|
*
|
-
|
|
|
2,385
|
|
-
|
*
|
*
|
-
|
EDURANT /
rilpivirine
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
10
|
|
11
|
-15.8%
|
-15.8%
|
-
|
|
|
41
|
|
44
|
-7.6%
|
-7.6%
|
-
|
Intl
|
|
220
|
|
236
|
-6.8%
|
-3.3%
|
-3.5%
|
|
|
953
|
|
920
|
3.6%
|
0.4%
|
3.2%
|
WW
|
|
230
|
|
248
|
-7.2%
|
-3.9%
|
-3.3%
|
|
|
994
|
|
964
|
3.1%
|
0.0%
|
3.1%
|
PREZISTA / PREZCOBIX
/ REZOLSTA / SYMTUZA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
380
|
|
433
|
-12.2%
|
-12.2%
|
-
|
|
|
1,508
|
|
1,587
|
-4.9%
|
-4.9%
|
-
|
Intl
|
|
135
|
|
136
|
-0.1%
|
3.0%
|
-3.1%
|
|
|
575
|
|
597
|
-3.6%
|
-6.0%
|
2.4%
|
WW
|
|
515
|
|
569
|
-9.3%
|
-8.5%
|
-0.8%
|
|
|
2,083
|
|
2,184
|
-4.6%
|
-5.2%
|
0.6%
|
OTHER INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
11
|
|
25
|
-55.9%
|
-55.9%
|
-
|
|
|
66
|
|
104
|
-36.0%
|
-36.0%
|
-
|
Intl
|
|
63
|
|
71
|
-10.9%
|
-10.0%
|
-0.9%
|
|
|
333
|
|
323
|
3.0%
|
-0.1%
|
3.1%
|
WW
|
|
74
|
|
96
|
-22.9%
|
-22.2%
|
-0.7%
|
|
|
399
|
|
427
|
-6.5%
|
-8.9%
|
2.4%
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
899
|
|
806
|
11.4%
|
11.4%
|
-
|
|
|
3,347
|
|
3,091
|
8.3%
|
8.3%
|
-
|
Intl
|
|
894
|
|
892
|
0.2%
|
3.2%
|
-3.0%
|
|
|
3,664
|
|
3,457
|
6.0%
|
3.9%
|
2.1%
|
WW
|
|
1,793
|
|
1,698
|
5.5%
|
7.1%
|
-1.6%
|
|
|
7,011
|
|
6,548
|
7.1%
|
5.9%
|
1.2%
|
CONCERTA /
Methylphenidate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
55
|
|
33
|
68.1%
|
68.1%
|
-
|
|
|
172
|
|
183
|
-5.8%
|
-5.8%
|
-
|
Intl
|
|
123
|
|
120
|
3.2%
|
6.0%
|
-2.8%
|
|
|
495
|
|
439
|
12.8%
|
10.1%
|
2.7%
|
WW
|
|
178
|
|
153
|
17.2%
|
19.4%
|
-2.2%
|
|
|
667
|
|
622
|
7.3%
|
5.4%
|
1.9%
|
INVEGA SUSTENNA /
XEPLION /
INVEGA TRINZA / TREVICTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
668
|
|
610
|
9.5%
|
9.5%
|
-
|
|
|
2,550
|
|
2,314
|
10.2%
|
10.2%
|
-
|
Intl
|
|
361
|
|
355
|
1.5%
|
5.0%
|
-3.5%
|
|
|
1,472
|
|
1,339
|
10.0%
|
6.9%
|
3.1%
|
WW
|
|
1,029
|
|
965
|
6.5%
|
7.8%
|
-1.3%
|
|
|
4,022
|
|
3,653
|
10.1%
|
9.0%
|
1.1%
|
RISPERDAL
CONSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
77
|
|
76
|
2.3%
|
2.3%
|
-
|
|
|
287
|
|
296
|
-2.9%
|
-2.9%
|
-
|
Intl
|
|
63
|
|
92
|
-30.3%
|
-26.4%
|
-3.9%
|
|
|
305
|
|
346
|
-11.8%
|
-13.1%
|
1.3%
|
WW
|
|
140
|
|
167
|
-15.6%
|
-13.4%
|
-2.2%
|
|
|
592
|
|
642
|
-7.7%
|
-8.4%
|
0.7%
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
99
|
|
88
|
11.7%
|
11.7%
|
-
|
|
|
338
|
|
298
|
13.3%
|
13.3%
|
-
|
Intl
|
|
346
|
|
326
|
6.2%
|
8.6%
|
-2.4%
|
|
|
1,391
|
|
1,334
|
4.3%
|
3.2%
|
1.1%
|
WW
|
|
445
|
|
414
|
7.4%
|
9.2%
|
-1.8%
|
|
|
1,729
|
|
1,632
|
6.0%
|
5.0%
|
1.0%
|
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,594
|
|
1,469
|
8.5%
|
8.5%
|
-
|
|
|
5,958
|
|
5,092
|
17.0%
|
17.0%
|
-
|
Intl
|
|
2,184
|
|
1,965
|
11.1%
|
15.2%
|
-4.1%
|
|
|
8,590
|
|
7,275
|
18.1%
|
15.3%
|
2.8%
|
WW
|
|
3,778
|
|
3,434
|
10.0%
|
12.3%
|
-2.3%
|
|
|
14,548
|
|
12,367
|
17.6%
|
16.0%
|
1.6%
|
DARZALEX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
867
|
|
692
|
25.3%
|
25.3%
|
-
|
|
|
3,169
|
|
2,232
|
42.0%
|
42.0%
|
-
|
Intl
|
|
778
|
|
561
|
38.9%
|
43.5%
|
-4.6%
|
|
|
2,854
|
|
1,958
|
45.8%
|
42.6%
|
3.2%
|
WW
|
|
1,645
|
|
1,253
|
31.4%
|
33.4%
|
-2.0%
|
|
|
6,023
|
|
4,190
|
43.8%
|
42.3%
|
1.5%
|
ERLEADA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
235
|
|
176
|
33.4%
|
33.4%
|
-
|
|
|
813
|
|
583
|
39.3%
|
39.3%
|
-
|
Intl
|
|
149
|
|
64
|
*
|
*
|
*
|
|
|
478
|
|
176
|
*
|
*
|
*
|
WW
|
|
384
|
|
241
|
59.8%
|
61.3%
|
-1.5%
|
|
|
1,291
|
|
760
|
70.0%
|
68.7%
|
1.3%
|
IMBRUVICA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
436
|
|
492
|
-11.3%
|
-11.3%
|
-
|
|
|
1,747
|
|
1,821
|
-4.0%
|
-4.0%
|
-
|
Intl
|
|
626
|
|
625
|
0.0%
|
3.4%
|
-3.4%
|
|
|
2,622
|
|
2,307
|
13.6%
|
10.4%
|
3.2%
|
WW
|
|
1,062
|
|
1,117
|
-5.0%
|
-3.1%
|
-1.9%
|
|
|
4,369
|
|
4,128
|
5.8%
|
4.1%
|
1.7%
|
ZYTIGA / abiraterone
acetate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
23
|
|
89
|
-74.2%
|
-74.2%
|
-
|
|
|
119
|
|
373
|
-68.1%
|
-68.1%
|
-
|
Intl
|
|
525
|
|
533
|
-1.4%
|
3.1%
|
-4.5%
|
|
|
2,178
|
|
2,097
|
3.9%
|
1.5%
|
2.4%
|
WW
|
|
548
|
|
622
|
-11.8%
|
-7.9%
|
-3.9%
|
|
|
2,297
|
|
2,470
|
-7.0%
|
-9.0%
|
2.0%
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
34
|
|
20
|
64.7%
|
64.7%
|
-
|
|
|
110
|
|
83
|
31.7%
|
31.7%
|
-
|
Intl
|
|
106
|
|
183
|
-42.0%
|
-39.2%
|
-2.8%
|
|
|
458
|
|
738
|
-37.9%
|
-38.7%
|
0.8%
|
WW
|
|
140
|
|
202
|
-31.3%
|
-28.8%
|
-2.5%
|
|
|
568
|
|
821
|
-30.8%
|
-31.5%
|
0.7%
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
PULMONARY
HYPERTENSION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
587
|
|
592
|
-0.7%
|
-0.7%
|
-
|
|
|
2,365
|
|
2,133
|
10.9%
|
10.9%
|
-
|
Intl
|
|
264
|
|
273
|
-3.6%
|
0.8%
|
-4.4%
|
|
|
1,085
|
|
1,015
|
6.9%
|
5.5%
|
1.4%
|
WW
|
|
851
|
|
865
|
-1.6%
|
-0.2%
|
-1.4%
|
|
|
3,450
|
|
3,148
|
9.6%
|
9.2%
|
0.4%
|
OPSUMIT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
286
|
|
279
|
2.0%
|
2.0%
|
-
|
|
|
1,147
|
|
1,008
|
13.7%
|
13.7%
|
-
|
Intl
|
|
162
|
|
173
|
-6.1%
|
-1.7%
|
-4.4%
|
|
|
672
|
|
631
|
6.6%
|
5.1%
|
1.5%
|
WW
|
|
448
|
|
452
|
-1.1%
|
0.6%
|
-1.7%
|
|
|
1,819
|
|
1,639
|
11.0%
|
10.4%
|
0.6%
|
UPTRAVI
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
264
|
|
263
|
0.0%
|
0.0%
|
-
|
|
|
1,056
|
|
955
|
10.5%
|
10.5%
|
-
|
Intl
|
|
46
|
|
38
|
21.9%
|
24.7%
|
-2.8%
|
|
|
181
|
|
138
|
31.1%
|
27.0%
|
4.1%
|
WW
|
|
310
|
|
301
|
2.7%
|
3.1%
|
-0.4%
|
|
|
1,237
|
|
1,093
|
13.1%
|
12.6%
|
0.5%
|
OTHER PULMONARY
HYPERTENSION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
38
|
|
49
|
-20.1%
|
-20.1%
|
-
|
|
|
163
|
|
169
|
-3.7%
|
-3.7%
|
-
|
Intl
|
|
56
|
|
63
|
-12.2%
|
-6.6%
|
-5.6%
|
|
|
232
|
|
247
|
-5.9%
|
-5.4%
|
-0.5%
|
WW
|
|
94
|
|
112
|
-15.6%
|
-12.4%
|
-3.2%
|
|
|
395
|
|
416
|
-5.0%
|
-4.7%
|
-0.3%
|
CARDIOVASCULAR /
METABOLISM / OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
813
|
|
935
|
-13.1%
|
-13.1%
|
-
|
|
|
3,192
|
|
3,509
|
-9.0%
|
-9.0%
|
-
|
Intl
|
|
261
|
|
317
|
-17.8%
|
-16.0%
|
-1.8%
|
|
|
1,268
|
|
1,369
|
-7.4%
|
-10.9%
|
3.5%
|
WW
|
|
1,074
|
|
1,253
|
-14.3%
|
-13.8%
|
-0.5%
|
|
|
4,460
|
|
4,878
|
-8.6%
|
-9.6%
|
1.0%
|
XARELTO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
644
|
|
629
|
2.5%
|
2.5%
|
-
|
|
|
2,438
|
|
2,345
|
4.0%
|
4.0%
|
-
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
WW
|
|
644
|
|
629
|
2.5%
|
2.5%
|
-
|
|
|
2,438
|
|
2,345
|
4.0%
|
4.0%
|
-
|
INVOKANA /
INVOKAMET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
59
|
|
159
|
-63.1%
|
-63.1%
|
-
|
|
|
308
|
|
564
|
-45.4%
|
-45.4%
|
-
|
Intl
|
|
60
|
|
58
|
3.8%
|
4.5%
|
-0.7%
|
|
|
254
|
|
231
|
9.9%
|
5.4%
|
4.5%
|
WW
|
|
120
|
|
217
|
-45.1%
|
-44.9%
|
-0.2%
|
|
|
563
|
|
795
|
-29.3%
|
-30.6%
|
1.3%
|
PROCRIT /
EPREX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
55
|
|
62
|
-12.8%
|
-12.8%
|
-
|
|
|
223
|
|
277
|
-19.7%
|
-19.7%
|
-
|
Intl
|
|
58
|
|
66
|
-13.0%
|
-11.7%
|
-1.3%
|
|
|
256
|
|
274
|
-6.8%
|
-10.1%
|
3.3%
|
WW
|
|
113
|
|
129
|
-12.9%
|
-12.2%
|
-0.7%
|
|
|
479
|
|
552
|
-13.3%
|
-14.9%
|
1.6%
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
55
|
|
85
|
-35.6%
|
-35.6%
|
-
|
|
|
223
|
|
323
|
-31.0%
|
-31.0%
|
-
|
Intl
|
|
143
|
|
194
|
-25.9%
|
-23.8%
|
-2.1%
|
|
|
758
|
|
864
|
-12.2%
|
-15.5%
|
3.3%
|
WW
|
|
198
|
|
278
|
-28.9%
|
-27.4%
|
-1.5%
|
|
|
981
|
|
1,186
|
-17.3%
|
-19.7%
|
2.4%
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
7,418
|
|
7,116
|
4.2%
|
4.2%
|
-
|
|
|
27,954
|
|
25,735
|
8.6%
|
8.6%
|
-
|
Intl
|
|
6,870
|
|
5,152
|
33.4%
|
36.9%
|
-3.5%
|
|
|
24,126
|
|
19,837
|
21.6%
|
18.8%
|
2.8%
|
WW
|
|
$
14,288
|
|
12,268
|
16.5%
|
17.9%
|
-1.4%
|
|
|
$
52,080
|
|
45,572
|
14.3%
|
13.1%
|
1.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
MEDICAL DEVICES
SEGMENT (2)
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INTERVENTIONAL
SOLUTIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
483
|
|
433
|
11.6%
|
11.6%
|
-
|
|
|
1,836
|
|
1,452
|
26.4%
|
26.4%
|
-
|
Intl
|
|
536
|
|
460
|
16.5%
|
18.8%
|
-2.3%
|
|
|
2,135
|
|
1,594
|
34.0%
|
29.8%
|
4.2%
|
WW
|
|
1,019
|
|
893
|
14.1%
|
15.3%
|
-1.2%
|
|
|
3,971
|
|
3,046
|
30.4%
|
28.2%
|
2.2%
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,305
|
|
1,352
|
-3.5%
|
-3.5%
|
-
|
|
|
5,126
|
|
4,779
|
7.3%
|
7.3%
|
-
|
Intl
|
|
851
|
|
839
|
1.5%
|
3.9%
|
-2.4%
|
|
|
3,462
|
|
2,984
|
16.0%
|
12.1%
|
3.9%
|
WW
|
|
2,155
|
|
2,191
|
-1.6%
|
-0.7%
|
-0.9%
|
|
|
8,588
|
|
7,763
|
10.6%
|
9.1%
|
1.5%
|
HIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
229
|
|
229
|
0.4%
|
0.4%
|
-
|
|
|
883
|
|
793
|
11.4%
|
11.4%
|
-
|
Intl
|
|
151
|
|
143
|
4.9%
|
6.5%
|
-1.6%
|
|
|
602
|
|
487
|
23.6%
|
18.9%
|
4.7%
|
WW
|
|
380
|
|
372
|
2.1%
|
2.7%
|
-0.6%
|
|
|
1,485
|
|
1,280
|
16.0%
|
14.3%
|
1.7%
|
KNEES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
208
|
|
216
|
-4.2%
|
-4.2%
|
-
|
|
|
787
|
|
743
|
5.9%
|
5.9%
|
-
|
Intl
|
|
135
|
|
129
|
4.6%
|
6.5%
|
-1.9%
|
|
|
538
|
|
427
|
26.1%
|
21.7%
|
4.4%
|
WW
|
|
342
|
|
345
|
-0.9%
|
-0.2%
|
-0.7%
|
|
|
1,325
|
|
1,170
|
13.3%
|
11.7%
|
1.6%
|
TRAUMA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
467
|
|
454
|
2.8%
|
2.8%
|
-
|
|
|
1,819
|
|
1,648
|
10.4%
|
10.4%
|
-
|
Intl
|
|
261
|
|
268
|
-2.4%
|
0.7%
|
-3.1%
|
|
|
1,066
|
|
966
|
10.4%
|
7.1%
|
3.3%
|
WW
|
|
728
|
|
722
|
0.9%
|
2.0%
|
-1.1%
|
|
|
2,885
|
|
2,614
|
10.4%
|
9.2%
|
1.2%
|
SPINE, SPORTS &
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
401
|
|
453
|
-11.4%
|
-11.4%
|
-
|
|
|
1,637
|
|
1,595
|
2.6%
|
2.6%
|
-
|
Intl
|
|
304
|
|
299
|
2.0%
|
4.3%
|
-2.3%
|
|
|
1,256
|
|
1,104
|
13.8%
|
9.9%
|
3.9%
|
WW
|
|
706
|
|
752
|
-6.1%
|
-5.2%
|
-0.9%
|
|
|
2,893
|
|
2,699
|
7.2%
|
5.6%
|
1.6%
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FOURTH
QUARTER
|
|
TWELVE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
SURGERY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
986
|
|
1,002
|
-1.7%
|
-1.7%
|
-
|
|
|
3,867
|
|
3,249
|
19.0%
|
19.0%
|
-
|
Intl
|
|
1,527
|
|
1,427
|
7.0%
|
8.7%
|
-1.7%
|
|
|
5,945
|
|
4,983
|
19.3%
|
15.6%
|
3.7%
|
WW
|
|
2,513
|
|
2,429
|
3.5%
|
4.4%
|
-0.9%
|
|
|
9,812
|
|
8,232
|
19.2%
|
17.0%
|
2.2%
|
ADVANCED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
457
|
|
456
|
0.5%
|
0.5%
|
-
|
|
|
1,761
|
|
1,535
|
14.9%
|
14.9%
|
-
|
Intl
|
|
735
|
|
660
|
11.2%
|
12.6%
|
-1.4%
|
|
|
2,861
|
|
2,304
|
24.1%
|
20.0%
|
4.1%
|
WW
|
|
1,192
|
|
1,116
|
6.8%
|
7.6%
|
-0.8%
|
|
|
4,622
|
|
3,839
|
20.4%
|
18.0%
|
2.4%
|
GENERAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
528
|
|
546
|
-3.4%
|
-3.4%
|
-
|
|
|
2,105
|
|
1,714
|
22.7%
|
22.7%
|
-
|
Intl
|
|
793
|
|
767
|
3.4%
|
5.3%
|
-1.9%
|
|
|
3,085
|
|
2,679
|
15.2%
|
11.8%
|
3.4%
|
WW
|
|
1,321
|
|
1,312
|
0.6%
|
1.7%
|
-1.1%
|
|
|
5,190
|
|
4,392
|
18.1%
|
16.1%
|
2.0%
|
VISION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
443
|
|
397
|
11.4%
|
11.4%
|
-
|
|
|
1,857
|
|
1,557
|
19.3%
|
19.3%
|
-
|
Intl
|
|
728
|
|
679
|
7.2%
|
10.8%
|
-3.6%
|
|
|
2,831
|
|
2,362
|
19.8%
|
18.8%
|
1.0%
|
WW
|
|
1,171
|
|
1,076
|
8.7%
|
11.0%
|
-2.3%
|
|
|
4,688
|
|
3,919
|
19.6%
|
19.0%
|
0.6%
|
CONTACT LENSES /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
316
|
|
289
|
9.4%
|
9.4%
|
-
|
|
|
1,398
|
|
1,213
|
15.2%
|
15.2%
|
-
|
Intl
|
|
518
|
|
507
|
1.9%
|
5.8%
|
-3.9%
|
|
|
2,043
|
|
1,781
|
14.7%
|
14.0%
|
0.7%
|
WW
|
|
833
|
|
796
|
4.6%
|
7.1%
|
-2.5%
|
|
|
3,440
|
|
2,994
|
14.9%
|
14.5%
|
0.4%
|
SURGICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
126
|
|
108
|
16.8%
|
16.8%
|
-
|
|
|
459
|
|
344
|
33.5%
|
33.5%
|
-
|
Intl
|
|
211
|
|
172
|
22.9%
|
25.4%
|
-2.5%
|
|
|
788
|
|
581
|
35.7%
|
33.3%
|
2.4%
|
WW
|
|
338
|
|
280
|
20.5%
|
22.1%
|
-1.6%
|
|
|
1,248
|
|
925
|
34.9%
|
33.4%
|
1.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL MEDICAL
DEVICES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3,216
|
|
3,184
|
1.0%
|
1.0%
|
-
|
|
|
12,686
|
|
11,036
|
14.9%
|
14.9%
|
-
|
Intl
|
|
3,643
|
|
3,405
|
7.0%
|
9.3%
|
-2.3%
|
|
|
14,374
|
|
11,923
|
20.6%
|
17.3%
|
3.3%
|
WW
|
|
$
6,859
|
|
6,589
|
4.1%
|
5.3%
|
-1.2%
|
|
|
$
27,060
|
|
22,959
|
17.9%
|
16.2%
|
1.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note: Columns
and rows within tables may not add due to rounding. Percentages
have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
The Company estimates that the inclusion of an additional week in
the 2020 fiscal year impacted fiscal fourth quarter 2021
comparative sales growth by
approximately -4% and impacted full year fiscal 2021 comparative
sales growth by approximately -1%.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Percentage greater
than 100% or not meaningful
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Operational
growth excludes the effect of translational currency
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3) Certain prior
year amounts have been reclassified to conform to current year
product disclosures
|
|
|
|
|
|
|
|
|
(4) Reported as U.S.
sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-reports-q4-and-full-year-2021-results-301467057.html
SOURCE Johnson & Johnson